Login to Your Account

Durata Pads Coffers Ahead of NDA; Kamada Files for U.S. IPO

By Jennifer Boggs
Managing Editor

Friday, April 12, 2013
With regulatory filings expected later this year for antibiotic dalbavancin, Durata Therapeutics Inc. continues to shore up its cash position. A month after inking a $20 million debt facility agreement, the Chicago-based biotech priced a $50 million public offering, selling 7.15 million shares priced at $7 apiece.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription